SGP
SpyGlass Pharma, Inc.
Price Chart
Latest Quote
$18.70
+0.50 (+2.75%)
Current Price
| Previous Close | $18.20 |
| Open | $18.36 |
| Day High | $19.14 |
| Day Low | $18.32 |
| Volume | 107,052 |
Stock Information
| Shares Outstanding | 33.43M |
| Total Debt | $1.58M |
| Cash Equivalents | $107.44M |
| Net Income | $-39.87M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $625.20M |
| EPS (TTM) | $-1.34 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $723.76M |
| Income | $-39.87M |
| Book/sh | $7.48 |
| Cash/sh | $3.21 |
| Employees | 65 |
Financial Ratios
| Quick Ratio | 12.57 |
| Current Ratio | 12.67 |
| Debt/Eq | 1.50 |
Returns & Margins
| ROA | -37.23% |
| ROE | -67.70% |
Ownership
| Insider Ownership | 4.28% |
| Institutional Ownership | 92.28% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.93 |
| P/B | 2.50 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $45.00 |
Technical Indicators
| SMA20 | $19.06 |
| SMA50 | $21.79 |
| RSI | 46.05 |
| ATR | 1.1479 |
| Shares Float | 6.48M |
| Short Float | 10.32% |
| Short Ratio | 18.94 |
| Rel Volume | 1.86 |
Performance History
| Week | +3.37% |
| Month | -11.79% |
| Quarter | -27.27% |
| YTD | -29.17% |
| 10 Years | -29.17% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $18.70 | 144,300 |
| 2026-06-17 | $18.20 | 108,900 |
| 2026-06-16 | $17.56 | 103,700 |
| 2026-06-15 | $18.94 | 143,800 |
| 2026-06-12 | $18.44 | 57,100 |
| 2026-06-11 | $18.09 | 77,800 |
| 2026-06-10 | $17.97 | 84,400 |
| 2026-06-09 | $18.19 | 70,100 |
| 2026-06-08 | $18.74 | 77,200 |
| 2026-06-05 | $18.78 | 77,500 |
| 2026-06-04 | $19.47 | 58,500 |
| 2026-06-03 | $18.56 | 47,100 |
| 2026-06-02 | $18.36 | 44,900 |
| 2026-06-01 | $18.32 | 44,700 |
| 2026-05-29 | $19.26 | 44,600 |
| 2026-05-28 | $19.84 | 41,400 |
| 2026-05-27 | $20.17 | 52,100 |
| 2026-05-26 | $20.62 | 86,600 |
| 2026-05-22 | $20.84 | 107,200 |
| 2026-05-21 | $22.05 | 79,900 |
| 2026-05-20 | $21.89 | 37,900 |
| 2026-05-19 | $21.20 | 45,200 |
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was incorporated in 2019 and is based in Aliso Viejo, California.
đ° Latest News
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 |
| Expenses | |||
| Total Expenses | $41,449,000 | $27,064,000 | $14,230,365 |
| Other Income Expense | $-1,526,000 | $-3,417,000 | - |
| Other Non Operating Income Expenses | $-1,526,000 | $-3,417,000 | - |
| Net Non Operating Interest Income Expense | $3,106,000 | $1,317,000 | $911,375 |
| Operating Expense | $41,449,000 | $27,064,000 | $14,230,365 |
| General And Administrative Expense | $12,266,000 | $7,080,000 | $4,270,759 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-39,869,000 | $-29,164,000 | $-13,318,990 |
| Net Interest Income | $3,106,000 | $1,317,000 | $911,375 |
| Interest Income | $3,106,000 | $1,317,000 | $911,375 |
| Normalized Income | $-39,869,000 | $-29,164,000 | $-13,318,990 |
| Net Income From Continuing And Discontinued Operation | $-39,869,000 | $-29,164,000 | $-13,318,990 |
| Total Operating Income As Reported | $-41,449,000 | $-27,064,000 | $-14,230,365 |
| Net Income Common Stockholders | $-39,869,000 | $-29,164,000 | $-13,318,990 |
| Net Income | $-39,869,000 | $-29,164,000 | $-13,318,990 |
| Net Income Including Noncontrolling Interests | $-39,869,000 | $-29,164,000 | $-13,318,990 |
| Net Income Continuous Operations | $-39,869,000 | $-29,164,000 | $-13,318,990 |
| Pretax Income | $-39,869,000 | $-29,164,000 | $-13,318,990 |
| Interest Income Non Operating | $3,106,000 | $1,317,000 | $911,375 |
| Operating Income | $-41,449,000 | $-27,064,000 | $-14,230,365 |
| Per Share | |||
| Diluted EPS | $-1.25 | $-1.62 | $-1.17 |
| Basic EPS | $-1.25 | $-1.62 | $-1.17 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-40,837,000 | $-26,793,000 | $-14,107,697 |
| Reconciled Depreciation | $612,000 | $271,000 | $122,668 |
| EBITDA (Bullshit earnings) | $-40,837,000 | $-26,793,000 | $-14,107,697 |
| EBIT | $-41,449,000 | $-27,064,000 | $-14,230,365 |
| Diluted Average Shares | $31,911,164 | $17,955,615 | $11,397,125 |
| Basic Average Shares | $31,911,164 | $17,955,615 | $11,397,125 |
| Diluted NI Availto Com Stockholders | $-39,869,000 | $-29,164,000 | $-13,318,990 |
| Tax Provision | $0 | $0 | $0 |
| Research And Development | $29,183,000 | $19,984,000 | $9,959,606 |
| Selling General And Administration | $12,266,000 | $7,080,000 | $4,270,759 |
| Other Gand A | $12,266,000 | $7,080,000 | $4,270,759 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $-98,837,000 | $-60,474,000 | $-32,985,518 |
| Total Assets | $115,866,000 | $23,318,000 | $41,149,466 |
| Total Non Current Assets | $7,098,000 | $5,912,000 | $534,607 |
| Other Non Current Assets | $492,000 | $453,000 | $86,116 |
| Non Current Deferred Assets | $2,715,000 | $0 | - |
| Current Assets | $108,768,000 | $17,406,000 | $40,614,859 |
| Prepaid Assets | $901,000 | $715,000 | $175,478 |
| Receivables | $431,000 | $423,000 | $122,906 |
| Other Receivables | $431,000 | $423,000 | $122,906 |
| Cash Cash Equivalents And Short Term Investments | $107,436,000 | $16,268,000 | $40,316,475 |
| Cash And Cash Equivalents | $96,358,000 | $16,268,000 | $15,848,682 |
| Other Current Assets | - | $229,265 | - |
| Debt | |||
| Total Debt | $1,582,000 | $3,897,000 | $0 |
| Long Term Debt And Capital Lease Obligation | $1,582,000 | $3,455,000 | $0 |
| Current Debt And Capital Lease Obligation | - | $442,000 | - |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $214,703,000 | $83,792,000 | $74,134,984 |
| Total Non Current Liabilities Net Minority Interest | $206,119,000 | $76,001,000 | $72,546,328 |
| Current Liabilities | $8,584,000 | $7,791,000 | $1,588,656 |
| Other Current Liabilities | $3,706,000 | $4,089,000 | $340,496 |
| Payables And Accrued Expenses | $2,696,000 | $1,978,000 | $639,161 |
| Payables | $2,696,000 | $1,978,000 | $639,161 |
| Accounts Payable | $2,696,000 | $1,978,000 | $639,161 |
| Equity | |||
| Common Stock Equity | $-98,837,000 | $-60,474,000 | $-32,985,518 |
| Total Equity Gross Minority Interest | $-98,837,000 | $-60,474,000 | $-32,985,518 |
| Stockholders Equity | $-98,837,000 | $-60,474,000 | $-32,985,518 |
| Retained Earnings | $-104,730,000 | $-64,861,000 | $-35,697,581 |
| Preferred Securities Outside Stock Equity | $204,537,000 | $72,546,000 | $72,546,328 |
| Other | |||
| Ordinary Shares Number | $31,911,164 | $31,911,164 | $31,911,164 |
| Share Issued | $31,911,164 | $31,911,164 | $31,911,164 |
| Tangible Book Value | $-98,837,000 | $-60,474,000 | $-32,985,518 |
| Invested Capital | $-98,837,000 | $-60,474,000 | $-32,985,518 |
| Working Capital | $100,184,000 | $9,615,000 | $39,026,203 |
| Capital Lease Obligations | $1,582,000 | $3,897,000 | $0 |
| Total Capitalization | $-98,837,000 | $-60,474,000 | $-32,985,518 |
| Additional Paid In Capital | $5,893,000 | $4,387,000 | $2,712,047 |
| Capital Stock | $0 | $0 | $16 |
| Common Stock | $0 | $0 | $16 |
| Long Term Capital Lease Obligation | $1,582,000 | $3,455,000 | $0 |
| Current Capital Lease Obligation | $0 | $442,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,182,000 | $1,282,000 | $608,999 |
| Net PPE | $3,891,000 | $5,459,000 | $448,491 |
| Accumulated Depreciation | $-1,114,000 | $-543,000 | $-271,200 |
| Gross PPE | $5,005,000 | $6,002,000 | $719,691 |
| Leases | $622,000 | $622,000 | $418 |
| Construction In Progress | $430,000 | $0 | - |
| Other Properties | $1,552,000 | $3,291,000 | - |
| Machinery Furniture Equipment | $2,401,000 | $2,089,000 | $719,273 |
| Properties | $0 | $0 | $0 |
| Other Short Term Investments | $11,078,000 | $0 | $24,467,793 |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-33,490,000 | $-24,018,000 | $-12,494,275 |
| Operating Activities | |||
| Operating Cash Flow | $-32,701,000 | $-22,027,000 | $-12,277,733 |
| Cash Flow From Continuing Operating Activities | $-32,701,000 | $-22,027,000 | $-12,277,733 |
| Operating Gains Losses | $5,000 | - | - |
| Investing Activities | |||
| Capital Expenditure | $-789,000 | $-1,991,000 | $-216,542 |
| Investing Cash Flow | $-11,794,000 | $22,261,000 | $-20,486,228 |
| Cash Flow From Continuing Investing Activities | $-11,794,000 | $22,261,000 | $-20,486,228 |
| Financing Activities | |||
| Repurchase Of Capital Stock | $-1,450,000 | $0 | - |
| Issuance Of Capital Stock | $127,336,000 | $0 | $40,009,994 |
| Financing Cash Flow | $124,585,000 | $185,000 | $39,769,970 |
| Cash Flow From Continuing Financing Activities | $124,585,000 | $185,000 | $39,769,970 |
| Net Other Financing Charges | $-1,471,000 | - | $-250,005 |
| Net Preferred Stock Issuance | $127,336,000 | $0 | $40,009,994 |
| Preferred Stock Issuance | $127,336,000 | $0 | $40,009,994 |
| Net Common Stock Issuance | $-1,450,000 | $0 | - |
| Other | |||
| Income Tax Paid Supplemental Data | $1,000 | $18,000 | $20,049 |
| End Cash Position | $96,358,000 | $16,268,000 | $15,848,682 |
| Beginning Cash Position | $16,268,000 | $15,849,000 | $8,842,673 |
| Changes In Cash | $80,090,000 | $419,000 | $7,006,009 |
| Proceeds From Stock Option Exercised | $170,000 | $185,000 | $9,981 |
| Common Stock Payments | $-1,450,000 | $0 | - |
| Net Investment Purchase And Sale | $-11,005,000 | $24,252,000 | $-20,269,686 |
| Sale Of Investment | $5,996,000 | $44,882,000 | $13,769,905 |
| Purchase Of Investment | $-17,001,000 | $-20,630,000 | $-34,039,591 |
| Net PPE Purchase And Sale | $-789,000 | $-1,991,000 | $-216,542 |
| Change In Working Capital | $2,448,000 | $1,338,000 | $112,297 |
| Change In Other Current Liabilities | $-441,000 | $201,000 | $-142,937 |
| Change In Other Current Assets | $-38,000 | $-367,000 | $-42,841 |
| Change In Payables And Accrued Expense | $3,121,000 | $2,344,000 | $444,150 |
| Change In Accrued Expense | $2,572,000 | $1,005,000 | $274,420 |
| Change In Payable | $549,000 | $1,339,000 | $169,730 |
| Change In Account Payable | $549,000 | $1,339,000 | $169,730 |
| Change In Prepaid Assets | $-186,000 | $-540,000 | $-59,277 |
| Change In Receivables | $-8,000 | $-300,000 | $-86,798 |
| Other Non Cash Items | $-209,000 | $621,000 | $-67,904 |
| Stock Based Compensation | $2,786,000 | $1,490,000 | $874,196 |
| Unrealized Gain Loss On Investment Securities | $1,526,000 | $3,417,000 | $0 |
| Depreciation Amortization Depletion | $612,000 | $271,000 | $122,668 |
| Depreciation And Amortization | $612,000 | $271,000 | $122,668 |
| Depreciation | $612,000 | $271,000 | $122,668 |
| Gain Loss On Sale Of PPE | $5,000 | $0 | - |
| Net Income From Continuing Operations | $-39,869,000 | $-29,164,000 | $-13,318,990 |
Fetched: 2026-06-19